📺 Panel Discussion from #ACC26: Dive into the 🆕 Dyslipidemia Guideline and VESALIUS-CV Late-Breaking Clinical Trial with Drs. Fred M. Kusumoto, R. Scott Wright and Eugene Yang.
Watch now on #ACCAnywhere TV! ➡️ https://bit.ly/4c2CRXU
Last weekend at #ACC26 was 😍
✨Celebrating & growing our community
✨Packed panel with Pfizer
✨Dr Roxana Mehran becoming @accintouch.bsky.social President
✨2025 Mentorship Award winner Dr. Preet Shaikh presenting research developed through the Awards
We're moving cardiology forward
#CardioSky
#ACC26 findings aren't just resonating within the cardiology community – they're reaching patients and the wider public too.
Here's a look at some of the standout studies making headlines in major consumer news outlets ➡️ https://bit.ly/4seoOEz #CardiologyMag
Calling all🫀AHFTC and purveyors of #critcarecards
Now that #ACC26 is over, come spend a weekend in NYC at the #1 cardiac hospital to learn about what's new and exciting #CardiogenicShock #Transplant #LVAD #TAH and more! ONE month away.
✍️Register now: nyulmc.org/heartfailurecme
#HeartFailure
Healio ended March on a high note - two major medical meetings, one weekend, a lot of coffee ☕
⚜️ American College of Cardiology #ACC26: www.healio.com/news/cardiol...
🗻 American Academy of Dermatology #AAD2026: www.healio.com/news/dermato...
@gohealio.bsky.social @accintouch.bsky.social
From LAAC vs. NOACs to hybrid AI adjudication, DCRI faculty shaped the science at #ACC26. Catch up on the sessions you may have missed: dcri.org/acc26 #CardioSky #HeartDisease
Prevention had its Expo Hall moment at #ACC26. PCKS9 inhibitors and AI retinal scans were presented alongside food-as-medicine interventions. All labeled prevention. All pointing to different futures. My latest for @statnews.com:
www.statnews.com/2026/04/02/c...
For people with heart failure with preserved ejection fraction, monitoring for early fluid accumulation in the lungs allowed for earlier intervention and thus fewer heart failure hospitalizations, a small randomized trial found. #ACC26 @accintouch.bsky.social
www.medpagetoday.com/meetingcover...
📣 #ACC26 Attendees: Catch up on sessions you missed with access to 200+ sessions from ACC.26 on demand. Your ACC.26 registration includes a three-month FREE trial to #ACCAnywhere.
Activate your ACC Anywhere subscription and continue your learning ➡️ https://bit.ly/3NSOkkM
👏 Congratulations to ACC Vice President Hani K. Najm, MD, MSc, FACC, and all our 🆕 esteemed ACC leaders!
🔗 More about the College's new officers and trustees who took office following Convocation at #ACC26: https://bit.ly/3NDAOS1
#ACCLeadership #CardioSky
#ACC26 Round Up: Eleven Original Articles were simultaneously published in NEJM and presented at this year’s American College of Cardiology Scientific Sessions in New Orleans. View the full thread for all @accintouch.bsky.social articles and bookmark this post for future reference.
In a new edition of ACC's Cardiology Hour, Dr. Valentin Fuster & a panel of experts break down the top trials released during #ACC26, such as STEMI-DTU, ORBITA-CTO, & more!
📽️: youtu.be/xvLFmv2-Et0?...
#JACC #CardioSky @accintouch.bsky.social
🔑Key Takeaways from #ACC26! Interested in discovering how the #latebreaking science presented at ACC 2026 will impact your practice? Read 10 high-level summaries with top takeaways drafted by SCAI experts➡️ www.scai.org/media-center/news-and-ar...
#CardioSky #CardioEd
From the 2nd to the 7th women presidents of @accintouch.bsky.social, this photo reflects progress, perseverance, and the power of representation.
Trailblazers who shaped cardiology and opened doors for others.
As we rise, we lift others & accelerate what comes next.
#ACC26 #WomenAsOne #CardioSky
Some conditions go undiagnosed for decades.
Dr. Ilan Kedan highlights a case where an aberrant right subclavian artery was identified at the bedside using POCUS. The right insight, at the right time, makes all the difference.
#ACC26 #POCUS #Cardiology #MedLife ❤️
Interesting data on the tafamidis-statin interaction--> related to BCRP substrates Presented at #ACC26 #MedIQACC26
#ACC26 Prem Soman presented in an LBCT session the updated outcomes from ATTRibute-CM OLE - patients on continuous acoramidis vs placebo to acoramidis out to 54 months.
The evolution of ATTR-CM treatment is a good story to tell
#MedIQACC26
#ACC26 Lots of progress in ATTR-CM, but there remains a large unmet need based on this survey
#MedIQACC26
#ACC26 consistent benefit from vutrisiran regardless of diastolic parameters at baseline. A post-hoc analysis from HELIOS-B
#MedIQACC26
#ACC26 Great data from @maz_hanna et al
Rate of conversion from PYP/HDP negative to positive - typically over 3 years, and CTS/SS identifies the high risk group. This supports our current practice of repeat evaluation once every 2 years in CTS+
#MedIQACC26
#ACC26 A super rare case from our group - Misfolded on the Right - delayed diagnosis due to assumptions of worsening status usually related to underlying disease
#MedIQACC26
#ACC26 low serum TTR had worse KCCQ, and improvement in TTR on acoramidis led to improved KCCQ
#MedIQACC26
#ACC26 longer term data from ATTRibute-CM/OLE on acoramidis effect on serum TTR and KCCQ-OS
#MedIQACC26
#ACC26 Vutrisiran resulted in better effect on KCCQ components compared to placebo in HELIOS-B
#MedIQACC26
#ACC26 AF/AFL in transthyretin amyloidosis is common and is associated with worse outcomes
#MedIQACC26
#ACC26 - Cystatin C-GFR reclassifies NAC staging in 20% of patients with transnthyretin amyloidosis
#MedIQACC26
